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Abstract 
The production of N-linked recombinant glycoproteins is possible in a variety of biotechnology host 
cells, and more recently in the bacterial workhorse, Escherichia coli. This methods chapter will 
outline the components and procedures needed to produce N- linked glycoproteins in E. coli, utilizing 
Campylobacter jejuni glycosylation machinery, although other related genes can be used with 
minimal tweaks to this methodology. To ensure a successful outcome, various methods will be 
highlighted that can confirm glycoprotein production to a high degree of confidence, including the 
gold standard of mass spectrometry analysis.  
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1 Introduction 
The process of glycosylation, a posttranslational modification estimated to be present on half of all 
human proteins [1. 2], can affect a wide variety of protein properties including its function, 
localization and half-life [3-5]. Due to these properties, 40 % of the drugs approved in the current 
recombinant therapeutics market are glycosylated, with this figure predicted to increase [6]. This 
sizeable market share means that glycoproteins contribute significantly to the biopharma industry, 
which in 2013 was calculated to be worth $US140 billion [7].  
 
Of the approved glycotherapeutics, approximately 70 % are currently being produced in the 
eukaryotic cell line, Chinese hamster ovary (CHO) cells [8], which, through the utilization of their 
inherent glycosylation machinery, can mimic human type glycans, yielding therapeutic proteins with 
the desired glycosylation profile that will not induce an immunogenic response in humans [9].  
In the non-glycosylated therapeutic protein market, the main host cell factory is E. coli, which 
generates around 30 % of the 151 recombinant therapeutics approved by either the EMA or the FDA 
[10]. With recent advancements in the synthetic biology toolkit for E. coli, this host now has the 
ability to express full length monoclonal antibodies [11, 12], and generate recombinant O- and N-
linked glycoproteins [13-17]. These new capabilities present the opportunity to generate recombinant 
glycoproteins within E. coli. 
 
The initial discovery of bacterial N-linked glycosylation in C. jejuni and its successful transfer into E. 
coli [16, 18] opened up this area of research. As the field has advanced and accumulated knowledge 
on the bacterial glycosylation system, variations on the initial system containing the defined pgl 
pathway allowed the first steps in creating a model cell chassis. This has provided the opportunity for 
researchers to experiment with different genetic components within the system, replacing them with 
alternative parts from a variety of organisms, including eukaryotes [14, 19]. This led to the creation of 
a wide range of different glycan structures that could be attached [14, 16, 19], with a commercially 
successful example of this coming from the generation of glyco vaccines by GlycoVaxyn [20, 21].  
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With an ever expanding number of glycan structures still being discovered in the archaeal and 
prokaryotic domains of life, the potential to transfer them to target proteins for currently unexplored 
uses is a promising prospect for the field [22, 23].  
 
Although the option to engineer this system is apparent, in order to be able to carry out bacterial N-
linked glycosylation, there are a few core components required. Firstly, the genes required for sugar 
biosynthesis within the cytoplasm must be functional [24]. Second of all, the glycosyltransferases 
which transfer these monosaccharides and sequentially build the glycan on the lipid anchor must be 
present [25]. An enzyme to flip the anchored glycan across to the periplasm needs to be expressed 
[26, 27], and finally, an oligosaccharyl transferase (OSTase) that transfers the glycans to the target 
protein must also be functional within the system [28]. The structure and composition of the glycan, 
how efficiently it is flipped across the membrane and ultimately transferred to the target protein, are 
dependent on the genes introduced [14, 29, 30]. Here, we will outline the required components for 
producing glycoproteins in E. coli based upon the original C. jejuni system.  
 
1.1 Oligosaccharyl Transferase and the Consensus Sequence that it can recognize within the 
Target Protein 
In eukaryotes, N-linked glycosylation occurs at the consensus site of N-X-S/T, where X can be any 
amino acid except proline. The recognition of this site and subsequent transfer of glycan onto the 
asparagine residue is dependent on a multi subunit (OSTase) complex with a core functional unit 
known as STT3 [31]. In bacteria, this OST is a large single protein, with the most commonly utilized 
transferase being a periplasm located, membrane bound protein called pglB [32-34]. The native form 
of this protein recognizes a stricter glycosylation sequon with the requirement of a negatively charged 
amino acid at the -2 position, giving the consensus sequence, D/E-X-N-X-S/T, again with X being 
any amino acid except proline. When thinking about utilizing this system for glycoprotein production, 
it is vital that this sequence is present, unless the machinery has been modified to include an OSTase 
that recognizes the eukaryotic glycosylation sequence [30]. Even so, this may not be sufficient for 
glycosylation to occur. Within eukaryotes, the process takes place in multiple steps as the protein is 
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folded through two eukaryotic organelles, the ER and golgi [35, 36], making it a cotranslational 
process [37]. Within these organelles, the glycan structure can be built up and subsequently trimmed 
down by processing enzymes before final glycans are added to produce the mature glycan structure 
[38]. In bacteria, glycosylation typically takes place in the periplasm of the cell [22], and is seen as a 
single step block transfer of the final glycan to the target protein [39], which occurs 
posttranslationally. Due to this occurring on a fully folded substrate, it requires the consensus 
sequence to be situated in a flexible region of the protein that is accessible to the OSTase [39]. 
 
1.2 Periplasmic Localization 
As mentioned in the previous section, attachment of the glycan onto the protein within bacteria occurs 
in the periplasm. Therefore, the target protein, glycan and OSTase need to be localized to this 
compartment of the cell. PglB, as highlighted previously, is a membrane bound protein located in the 
periplasm, so is already present. As for the target protein, there are multiple pathways available that 
will direct the target protein to this part of the cell, including the TAT export system [40], SRP 
pathway [41], and sec transport system [42]. The most utilized methodology is the sec transport 
system, which requires the addition of a 22 amino acid leader sequence at the N-terminus of the 
polypeptide chain. This can be engineered through molecular cloning of the expression plasmid, but it 
is recommended that protein expression and translocation rates be attenuated prior to glycoprotein 
production. Finally, the glycan of interest must be present in the periplasm. Within the bacterial 
system, the glycans are sequentially built upon an undecaprenyl-pyrophosphate (UND-pp) lipid 
anchor by various glycosyltransferases. Depending on the glycan structure, certain sugar biosynthesis 
genes must also be expressed that utilize molecules from the central carbon metabolism, modifying 
them to generate any unnatural glycan precursors such as bacillosamine, as well as the common 
monosaccharides like UDP-GlcNAc [43]. Once these have been generated, the glycosyltransferases 
transfer them to the glycan being built upon the lipid anchor. Once the glycans are attached, the UND-
pp linked glycan molecule can be flipped across the inner membrane by a flippase, such as the C. 
jejuni pglK [34], or the native E. coli protein wzX [44] so the glycan now faces the periplasm [19]. 
With wzX and waaL, E. coli has a native system that utilizes periplasmic UND-pp linked glycans for 
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attachment to a lipid A core, for subsequent presentation on the cell surface [15]. It is therefore 
recommended that for recombinant N-linked glycoprotein expression, the competing protein that 
transfers the glycans to the lipid A core, waaL, is removed as seen in the W3110 mutant, CLM24 
[15]. The presence of waaL may be utilized to detect the presentation of glycans on the surface as a 
means of checking whether they are being expressed (or not) [32, 45]. 
 
1.3 Conclusion of Requirements 
The target recombinant protein must contain an asparagine residue situated in a consensus sequence, 
located in a flexible region of the protein, so that the OSTase of choice is able to recognize and bind. 
Once expressed, it must also be directed to the periplasm for this type of glycosylation to occur, which 
can be achieved by utilizing a number of export systems. Alongside expression of the target protein, 
glycosylation machinery must be incorporated into the cell, containing any genes needed for specific 
sugar biosynthesis, the required glycosyltransferases to build the glycan, a flippase that can recognize 
the glycan as a substrate, and an OSTase that will also recognize the glycan. This should all preferably 
take place in a bacterial strain where the waaL pathway is inhibited, unless glycan production is being 
checked by cell surface display. 
 
1.4 General Analysis 
In order to determine if the target protein has been successfully glycosylated, it is necessary to 
perform a periplasmic extraction, to release proteins that have the potential to be glycosylated. In 
order to determine whether N-glycosylation of the target protein is successful, a number of 
methodologies can be applied with varying degrees of speed and accuracy. These include western 
blots, where a mass shift for the addition of a glycan is observed [32], lectin peroxidase screen 
whereby a lectin that binds to a target glycan is bound [32] or the gold standard is the use of mass 
spectrometry, which can provide both protein sequence and glycan information [33]. By following the 
methodology and workflow stated (see Figure 1), the user should be able to generate N-linked 
glycoproteins in E. coli and validate this production using a variety of techniques. For more details on 
bacterial glycosylation please refer to this extensive review paper [46].  
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2 Materials 
All solutions should be prepared using either nuclease-free water or HPLC grade water along with 
analytical grade reagents. All solutions should be made up at room temperature unless otherwise 
stated. All examples and methodologies listed are for the generation of IFNܤEZLWKDQN-linked 
glycan structure of GalNAc5GlcNAC within E. coli, utilizing the plasmids pJExpressIFNъE and 
pACYCpgl2.  
 
2.1 General and Experiment Specific Reagents, Strains and Plasmids 
2.1.1 Antibiotic Stock Solutions 
1. 50 mg/mL Kanamycin, filter sterilized. 
2. 30 mg/mL Chloramphenicol in 100 % ethanol.  
 
2.1.2 Bacterial Strains 
1. E. coli W3110. 
2. E. coli CLM24. 
  
2.1.3 Glycosylation Machinery 
1. pACYCpgl2. 
  
2.1.4 Target Protein 
1. pJexpressIFNܤ2b. 
 
2.2 Cell Surface Expression of Glycans 
1. Luria Broth (10 g/L tryptone, 10 g/L NaCl 5 g/L yeast extract).  
2. Petri dishes. 
3. Protran Nitrocellulose membranes (Fisher Scientific). 
4. PBS containing 2 % (v/v) TWEEN® 20. 
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5. PBS with 0.05 % (v/v) TWEEN®  20, 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2 and ȝJof 
soybean agglutinin lectin peroxidase. 
6. ,PPRELORQchemiluminescent HRP (Fisher Scientific). 
7. ,PDJH4XDQW57(&/*(+HDOWKFDUHILWWHGZLWKWHPSHUDWXUHFRROHG-bit CCD Camera. 
8. 1-Step TMB Ultra blotting solution (Thermo Fisher Scientific). 
 
2.3 Target Protein Expression and Localization  
1. Luria Broth: 10 g/L Tryptone, 10 g/L NaCl 5 g/L Yeast extract.  
2. 1 mM IPTG.  
 
2.4 Periplasmic Protein Extraction and Quantification 
2.4.1 Extraction 
1. Periplasmic lysis buffer composed of 20 % (w/v) sucrose, 30 mM Tris-HCl, pH 8.0, and 1 x 
HALT (Pierce) in HPLC grade water. 
2. Centrifuge capable of spinning 50 mL falcon tubes at 3,000 x g, 4°C. 
 
2.4.2 Quantification  
1. Bradford reagent (Sigma Aldrich). 
2. RC DC protein assay kit II (Bio-Rad). 
 
2.5 SDS-PAGE Gels and Analysis  
2.5.1 SDS-PAGE 
1. NuPAGE Novex 4-12 % Bis-Tris protein gels, 1.0 mm, 12 well (Life Technologies). 
2. 20 x Novex MOPS SDS running buffer (Life Technologies). 
3. Novex Sharp Pre-stained protein standard (Life Technologies). 
4. Hoefer SE300 miniVE integrated vertical electrophoresis unit (Hoefer Inc). 
5. Centrifuge capable of spinning 1.5 mL microcentrifuge tubes at 13, 000 x g. 
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2.5.2 Western Blotting 
1. L%ORW*HO7UDQVIHU'HYLFH7KHUPR)LVKHU6FLHQWLILF. 
2. L%ORW*HO7UDQVIHU6WDFNV7KHUPR)LVKHU6FLHQWLILF. 
3. Blocking Buffer consisting of: 5 % (w/v) blocking powder (Bio-Rad) in TBS 0.05 % (v/v) 
Tween® 20. 
4. 6 x Histidine HRP linked antibody (Abcam). 
5. 1-Step TMB Ultra blotting solution (Thermo Fisher scientific). 
 
2.5.3 Lectin Screen  
1. L%ORW*HO7UDQVIHU'HYLFH7KHUPR)LVKHU6FLHQWLILF. 
2. L%ORW*HO7UDQsfer Stacks (Thermo Fisher Scientific). 
3. Protran Nitrocellulose membranes from (Thermo Fisher Scientific). 
4. PBS containing 2 % (v/v) TWEEN® 20 (Sigma Aldrich). 
5. PBS with 0.05 % (v/v) TWEEN®  20, 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2 and ȝJof 
soybean agglutinin lectin peroxidase (Sigma Aldrich). 
6. ,PPRELORQ chemiluminescent HRP (Fisher Scientific). 
7. ,PDJH4XDQW57(&/*(+HDOWKFDUHILWWHGZLWKWHPSHUDWXUHFRROHG-bit CCD Camera. 
8. 1-Step TMB Ultra blotting solution (Thermo Fisher scientific). 
 
2.6 Mass Spectrometry Analysis  
2.6.1 In-Solution Digest 
1. 100 mM ammonium bicarbonate made in HPLC grade water. 
2. Protein Lobind tubes (Eppendorf). 
3. 50 mM DTT stock solution. 
4. 100 mM Iodoacetamide stock solution. 
5. Trypsin solution made using lyophilised trypsin protease, MS grade (Pierce). 
6. 94.5 % (v/v) HPLC grade H2O, 5 % (v/v) acetonitrile, 0.5 % (v/v) TFA. 
7. Water bath 
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8. Benchtop microcentrifuge for 1.5 mL microcentrifuge tubes 
 
2.6.2 C18 Clean Up 
1. 3LHUFH&6SLQ&ROXPQV7KHUPR)LVKHU6FLHQWLILF. 
2. Protein Lobind tubes (Eppendorf). 
3. Centrifuge capable of spinning down 1.5 mL microcentrifuge tubes at 13, 000 x g. 
4. Vacuum concentrator centrifuge (Eppendorf) 
 
2.6.3 LC-MS 
1. Sonicating water bath 
2. Vortex mixer 
3. Centrifuge capable of spinning down 1.5 mL microcentrifuge tubes at 13, 000 x g. 
4. Automated LC vials. 
5. Automated LC vial caps. 
6. maXis Q-ToF mass spectrometer (Bruker Daltonics). 
7. Ultimate 3000 HPLC system (Dionex). 
8. HPLC buffer A consisting of: 96.9% HPLC grade water, 3% Acetonitrile, 0.1% Formic acid 
9. HPLC buffer B consisting of: 3% HPLC grade water, 96.9% Acetonitrile, 0.1% Formic acid 
 
3 Methods 
All examples and methodologies listed are for the generation of IFNܤEZLWKDQN-linked glycan 
structure of GalNAc5GlcNAC within E. coli, utilizing the plasmids pJExpressIFNъE and 
pACYCpgl2. 
3.1 Cell Surface Expression of Glycans  
If checking glycan production, use bacterial strain W3110. If checking waaL deletion, use your 
modified strain or in our case CLM24 (see Figures 2 and 3). 
1. Transform the desired E. coli strain with pACYCpgl2.  
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2. Inoculate 1 mL of LB, with the appropriate antibiotics, in a sterile 1.5 mL centrifuge tube 
with a colony of the bacterial strain containing pACYCpgl2. 
3. Incubate the tube at 37 °C for 16 hours in a shaker at 180 rpm. 
4. Measure the O.D. 600 and normalize the O.D. down to 0.6 using sterile LB. 
5. Dilute the cells by a factor of 1 in 75,000 to a final volume of 1 mL. 
6. Take 100 µL of the diluted culture and streak out onto an LB agar plate with correct 
antibiotics and leave to incubate for 16 hours at 37 °C (see Notes 1 and 2). 
7. Soak a piece of nitrocellulose paper, cut to fit inside a petri dish, for 5 mins in the required 
antibiotics for the maintenance of the plasmid in the strain.  
8. Place the nitrocellulose paper in a flow hood for 5 mins before placing the paper over the 
bacterial colonies using a clean pair of laboratory tweezers, and incubating for 3 hours at 37 
°C (see Note 3).   
9. Remove the nitrocellulose paper from the agar plate and block the membrane in PBS 
containing 2 % (v/v) TWEEN® 20 for 2 mins at 20 °C. 
10. Wash the membrane twice (10 mins each) in PBS. 
11. Incubate the membrane in PBS with 0.05 % (v/v) TWEEN® 20, 1 mM CaCl2, 1 mM MnCl2,  
1 mM MgCl2 and 3 µg of soybean agglutinin lectin peroxidase (specific for GalNAc) for 16 
hours at 20 °C (see Note 4). 
12. Wash the membrane for 2 x 10 mins in PBS. 
13. 'HWHFWFRORQLHVXVLQJ,PPRELORQFKHPLOXPLQHVFHQW+53VXEVWUDWHZLWK,PDJH4XDQW57
ECL (GE Healthcare), fitted with a cooled 16-bit CCD camera. 
14. If this type of camera is not available, the screen can be developed using approximately 10 
mL TMB-Ultra Blotting solution and leaving the membrane to develop for between 5-30 mins 
depending on the desired intensity and the level of background development. 
15. Wash with 2 x 5 mins washes with HPLC grade water to stop development of the membrane 
(see Note 5). 
 
3.2 Target Protein Expression and Localization 
 11 
3.2.1 Bacterial Growth and Protein Expression  
 Required to check protein of interest is being expressed and translocated to the periplasm (see Figure 
4). 
1. Inoculate 10 mL of LB containing the appropriate antibiotics with a colony of CLM24 
pJexpressIFNъE and grow for 16 hours at 37 °C with shaking at 180 rpm. 
2. Using the starter culture, inoculate 100 mL of LB containing the appropriate antibiotics and 
leave to grow at 37 °C with shaking at 180 rpm. 
3. When the O.D. 600 of the culture reaches 0.5, induce target protein expression with 1 mM 
IPTG. 
4. Leave the bacteria to express the protein of interest for 4 hours at 30 °C with shaking at 180 
rpm. 
5. Measure the final O.D. 600 of the culture, collecting 40 O.D.¶VZRUWKRIWKHFXOWXUHE\
spinning at 3,000 x g for 10 mins at 4 °C.  
6. Discard supernatant and continue to periplasmic protein extraction (see Note 6). 
  
3.2.2 Periplasmic Protein Extraction 
1. Gently resuspend the bacterial pellet in 1 mL of ice cold periplasmic lysis buffer, keeping the 
suspension in a 50 mL Falcon tube. 
2. Leave the pellet to gently roll on ice for 1.5 ± 2 hours. 
3. Spin down the cell debris at 3,000 x g for 10 mins at 4 °C, collecting the supernatant as the 
periplasmic extract (see Note 7).  
4. Pellet can be retained and the rest of the soluble fraction extracted to analyze the quantity of 
the target protein that has not been exported to the periplasm but has still been expressed.  
  
3.2.3 Quantification of the Periplasmic Extract 
Many common laboratory methods can be used here including a Bradford assay, RC/DC assay or 
nanodrop. Due to the frequent nature of these protocols, we advise that the researcher follows the 
detailed protocols that are widely available for these quantification techniques.  
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3.2.4 SDS-PAGE  
1. Pre-cast protein gels were used to run the gel based analysis. 
2. In a single LoBind 1.5 mL centrifuge tube, add the required volume of the periplasmic extract 
to place 5 µg of protein into the tube. Along with the sample add, 5 µL of 4 x LDS sample 
buffer, as well as 2 µL of 10 x reducing agent. Using distilled water, make the total volume up 
to 24 µL. 
3. Aliquot 10 µL of pre-stained protein standard into a fresh LoBind tube. 
4. Boil the samples and protein ladder for 10 mins at 70 °C. 
5. Leave the samples to cool before spinning all tubes down at 13,000 x g for 1 min. 
6. Load the gel into the gel tank and fill the internal chamber with fresh 1 x MOPS SDS running 
buffer (see Note 8). Fill the rest of the tank with 1 x MOPS SDS running buffer. Remove the 
plastic comb from the top of the gel and discard (see Note 9). 
7. Load protein ladder and samples onto the protein gel (see Note 10). 
8. Place the lid on top of the gel tank and run the gel at a constant 200 V for 50 mins (see Note 
11). 
9. Following the running of the gel, remove the gel tank lid, remove the plastic encased gel and 
carefully open along the seam at the edge of the casing. Remove the gel and place into a clean 
plastic container (see Note 12). Discard the used plastic casing. 
 
3.2.5 Western Blotting 
1. Western blotting will be conducted using the Invitrogen iBlot system and compatible transfer 
stacks. 
2. Briefly wash the acrylamide gel with 2 x MilliQ grade water to remove any excess SDS 
3. Following the manufacturer¶s protocol place the protein gel onto the membrane and complete 
the stack setup (see Note 13). 
4. Fasten lid and transfer the proteins onto the nitrocellulose membrane using the P3 transfer 
program for a run time of 7 mins.  
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5. Once run, discard all of the excess stack, including the gel, and using tweezers, carefully 
remove the membrane and submerge it in sufficient blocking buffer and leave rocking in this 
solution for 1 hour at room temperature (see Note 14). 
6. Wash the membrane with 3 x washes in TBS-T (0.05 % (v/v) Tween 20) for 10 mins each at 
room temperature, discarding the wash solution after each repeat.  
7. During the second wash, run a 1 in 10,000 dilution of the 6 x Histidine residue antibody in 20 
mL blocking buffer and place on the rocker during the rest of the wash steps. 
8. Remove the final wash solution and cover the membrane in the antibody solution. 
9. Leave this to incubate at 4 °C for 16 hours, preferably with gentle shaking. 
10. Discard the antibody solution and conduct 5 x 5 mins wash steps with TBS-T (0.05 % (v/v) 
Tween 20). 
11. Post washing, cover the membrane with approximately 10 mL of TMB-Ultra Blotting 
solution, leaving the membrane to develop for between 5-30 mins, depending on the desired 
intensity and the level of background development.  
12. Wash with 2 x 5 mins washes with HPLC grade water to stop development of the membrane. 
 
3.3 Expression of Glycoprotein 
See section 3.2.1 as the protocol for this is the same needed for glycoprotein expression except the 
starting bacterial strain must contain the plasmids required for both the target protein expression and 
the glycosylation machinery. Due to the presence of two plasmids, an extra antibiotic will be required 
for plasmid maintenance. If a mass spectrometry approach is going to be utilized for glycoprotein 
validation, it is important that when extracting the periplasmic proteins (section 3.2.2) no protease 
inhibitor cocktail is present in the lysis buffer mentioned earlier and that the sample is kept cold at all 
times (see Note 15). 
 
3.4 Validation of Glycoprotein Production using Gel based methods 
3.4.1 Western Blot Analysis  
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Expecting to see multiple bands compared to the control due to the mass shift that occurs with the 
attached glycan (see Figures 5 and 6). Run subsequent quantification steps (section 3.2.3), SDS-
PAGE (section 3.2.4) and Western blot (section 3.2.5) analysis as outlined above as well as a lectin 
screen specific to the sugars incorporated in the glycan. 
 
3.4.2 Lectin Screen 
Sugar specific lectin should bind to the glycans if present.  
1. Follow the same protocol as the western blotting up to step 5 with dismemberment of the 
blotting stack but instead of placing the membrane in the western blocking buffer, the 
membrane must be washed with PBS containing 2 % (v/v) Tween 20 for 2 mins at room 
temperature. 
2. Post blocking, wash the membrane twice with PBS for 10 mins at room temperature. 
3. Incubate the membrane for 16 hours at room temperature on a shaker in PBS with 0.05 % 
(v/v) TWEEN® 20, 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2 and 3 µg of soybean agglutinin 
lectin peroxidase (specific for GalNAc). 
4. Repeat the wash steps conducted in step 2 before covering the membrane with approximately 
10 mL of TMB-Ultra Blotting solution, leaving the membrane to develop for between 5-30 
mins depending on the desired intensity and the level of background development.  
5. Wash with 2 x 5 mins washes with HPLC grade water to stop development of the membrane. 
 
3.5 Validation of Glycoprotein Production using Mass Spectrometry Analysis 
Expecting to see the presence of diagnostic ions correlating to the sugars involved in the glycan (see 
Figures 5 and 7).  
3.5.1 In-Solution Digest 
1. In a single LoBind 1.5 mL centrifuge tube, add the required volume of the periplasmic extract 
to place 5 µg of protein into the tube.  
2. Make up the total volume to 40 µL using 100 mM ammonium bicarbonate. 
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3. Add a sufficient quantity of 50 mM DTT to achieve a final DTT concentration of 4 mM in the 
final solution. 
4. Incubate for 60 mins in a 56 °C water bath.  
5. Gently spin down at 1,000 x g for 1 min  
6. Add a sufficient quantity of 100 mM Iodoacetamide to achieve a final Iodoacetamide 
concentration of 8 mM in the final solution. 
7. Incubate in the dark at room temperature for 30 mins.  
8. Gently spin down at 1,000 x g for 1 min  
9. Add the protease at a ratio of 1:25 (protease:protein)  
10. Leave digest for 18 hours at 37 °C 
11. Dry down the samples in a vacuum concentrator centrifuge (see Note 16).  
12. Resuspend samples in 94.5 % (v/v) HPLC grade water, 5 % (v/v) ACN and 0.5 % (v/v) TFA 
 
3.5.2 C18 Clean Up 
Prior to mass spectrometry analysis, the sample should undergo a C18 clean up procedure. Due to the 
frequency of this technique and the wide range of columns available, it is recommended that the 
researcher follows the protocol that is supplied by the manufacturer. A recommended column is given 
in section 2.6.2. 
 
3.5.3 LC-MS 
1. Add 10 - 20 µL of 94.5 % (v/v) HPLC grade water, 5 % (v/v) ACN and 0.5 % (v/v) TFA to 
the dried peptides post C18 cleanup. 
2. Sonicate and vortex the samples for a minute each and then centrifuge the tubes at 13,000 x g 
for 30 secs to pool the liquid at the bottom of the LoBind centrifuge tube. 
3. Transfer liquid into a vial compatible with the automated LC system (see note 17). 
 
Using a maXis Q-TOF mass spectrometer (Bruker), perform high selectivity pseudo-selective reaction 
monitoring (pSRM) of the targeted glycopeptides. 
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3.5.4 Pseudo-Selective Reaction Monitoring (pSRM) 
1. Select the correct m/z values for the desired glycopeptides (see Note 18) and operate the Q-
TOF in MRM mode with an m/z window of 2 m/z. 
2. Run the mass spectrometer in positive mode with an m/z window of 3. 
3. Implement a rolling collision energy of 100-150 % with an MRM scan mode. 
4. Start online HPLC with 5 % of HPLC buffer B and 95 % of HPLC buffer A and run for 5 
min.  
5. Run a 30 min gradient program, increasing the concentration of HPLC buffer B up to 90 %. 
6. Once the gradient is at 90 % of HPLC buffer B, maintain that level for 10 mins. 
7. End the program by returning the HPLC buffer B concentration to 5 %. 
 
3.5.5 Data Analysis 
1. Select pSRM scans obtained from the analysis in subheading (section 3.5.4) and analyze 
using DataAnalysis v.4.1. 
2. Identify diagnostic ions present for the sugars generated in the expected glycan structure 
(204.08 for HexNAc, 366.14 for HexHexNAc) in MRM scans that add up to the expected m/z 
value for the glycopeptide. 
 
4 Notes 
1. This dilution factor should be significant enough to achieve single, non-touching colonies on 
the plate. If this is not the case, alterations may need to be made.  
2. If very small colonies are seen, leave them to grow for another few hours to become more 
established. 
3. Make sure tweezers are ethanol wiped before use and try to remove any air bubbles that can 
interfere with transfer.  
4. Solution containing soybean agglutinin lectin peroxidase can be cloudy when all components 
are mixed together. 
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5. Try to take an image of the developed gel as soon as possible after development, if left the 
blot may dry out or continue to develop if not washed properly.  
6. Try to remove as much residual LB as possible. 
7. Supernatant may need to be centrifuged a second time to ensure no cell debris is present in the 
periplasmic extract as it can late interfere with quantification. 
8. Ensure no leaks are present when filling the internal volume of the SDS-PAGE gel. This is an 
LQGLFDWLRQWKDWWKHJHOLVQ¶WVHDOHGLQSURSHUO\. 
9. Carefully remove the plastic comb to expose the wells in the SDS-PAGE gel. Wells are very 
delicate and easily damaged. 
10. Protein loading tips (Bio-Rad) are recommended for loading SDS-PAGE gels. 
11. If the target protein has a large MW protein, the gel can be run for longer to separate out 
bands of interest from one another more distinctly. Pgl2 glycans (GalNAc5GlcNAC) are 
roughly 1.2 kDa. 
12. Handle SDS-PAGE gel carefully as it is extremely delicate and partial to breaking (ripping). 
Wetting heavily with distilled water is advised to prevent this occurring. 
13. Ensure that when building up the stacks there are no air bubbles between layers as they can 
interfere with the transfer. 
14. Coloured protein ladder should now be visible on the membrane and no longer present in the 
acrylamide gel. 
15. No protease inhibitor cocktail should be used as it may interfere with the protease used for 
protein digestion prior to mass spectrometry analysis.  
16. At this point, the dried peptides can be stored at -20 °C and be analyzed at a later date. 
17. Ensure there are no bubbles present in the LC vials once the sample has been transferred into 
it. 
18. Be very careful when calculating MRM values. Make use of an in silico tool to calculate the 
m/z values for different peptides, taking into account the protease used, chemical 
modifications and the glycan structure used. 
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Figure Captions 
 
Figure 1. A workflow showing all the key points required in designing, generating and validating the 
expression of recombinant N-linked glycoproteins in E. coli.  
 
Figure 2. Diagrammatic workflow outlining the strains for the glycan production screen.  
 
Figure 3. Cell surface expression of glycans and confirmation of the production of a waaL knockout 
strain. (A) Cell surface screening with a functional waaL pathway showing that functional glycan 
machinery is being expressed. (B) Cell surface screening to show that glycans produced are not being 
exported, confirming the inhibition of the waaL pathway.  
 
Figure 4. Diagrammatic workflow outlining the process to check the target protein expression and 
localisation.  
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Figure 5. Diagrammatic workflow outlining the process of glycoprotein production and validation.  
 
Figure 6. Validation of glycoprotein production using Western Blotting. (A) Expression of the target 
protein without the presence of the glycosylation machinery. (B) Expression of the target protein with 
the glycosylation machinery producing the multiple glycoforms.  
 
Figure 7. Mass spectrometry validation of glycoprotein production. Spectra of a tryptically digested 
Interferon Į2b glycopeptide with the diagnostic oxonium ions of 204 and 366 highlighted.   
 
